Financials

	2021	2022
Net sales	-	-
Net income	-3.66Cr -2.64Cr -2.27Cr -2.15Cr -1.95Cr -251.97Cr -3.68Cr -26Cr -9.83Cr -128.19Cr -9.91Cr -9.69Cr -405.08Cr	-3.8Cr -2.74Cr -2.36Cr -2.23Cr -2.03Cr -261.63Cr -3.82Cr -27Cr -10Cr -133.1Cr -10Cr -10Cr -420.6Cr
Net Debt	-1.9Cr -1.37Cr -1.18Cr -1.12Cr -1.01Cr -130.58Cr -1.91Cr -13Cr -5.09Cr -66Cr -5.13Cr -5.02Cr -209.93Cr	76.74L 55.32L 47.66L 45.13L 40.9L 53Cr 77.13L 5.36Cr 2.06Cr 27Cr 2.08Cr 2.03Cr 85Cr

Company Profile

IMV Inc. is a Canada-based company. The Company has sold all of its assets. It is not engaged in any business operations.

Employees

Sector

Date	Price	Change	Volume
04/26/04	$0.000001	0.00%	470

Delayed Quote OTC Markets

Market Closed - OTC Markets 07:31:20 04/09/2026 pm IST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-

24/24/24	OPEC excited about Namibia partnership, offers support	RE
16/23/16	IMV Inc., Q4 2022 Earnings Call, Mar 16, 2023

24/24/24	OPEC excited about Namibia partnership, offers support	RE
16/23/16	IMV Inc., Q4 2022 Earnings Call, Mar 16, 2023
11/22/11	IMV Inc., Q3 2022 Earnings Call, Nov 11, 2022
11/22/11	IMV Inc., Q2 2022 Earnings Call, Aug 11, 2022
29/22/29	IMV Inc. - Shareholder/Analyst Call

04/23/04	IMV Accepts an Offer from its Secured Lenders for the Sale of its Intellectual Property Assets	AQ
14/19/14	IMV Inc. : to Present at Two Upcoming Investor Conferences	BU
12/19/12	Imv : New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV’s DPX-Survivac in Combination with Merck’s Keytruda in Patients with DLBCL	BU

Manager	Title	Age	Since
Stéphane Fiset CTO	Chief Tech/Sci/R&D Officer	-	-
Tracy Sherren SEC	Corporate Secretary	60	-
Marie-Eve Charrois LAW	General Counsel	-	-

Director	Title	Age	Since
Markus Warmuth BRD	Director/Board Member	55	06/11/2018
Michael Bailey CHM	Chairman	60	01/05/2022
Michael Kalos BRD	Director/Board Member	64	11/05/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
06/04/23	Shabnam Kazmi	Option	Director	48,259	0.4121%
06/04/23	Michael Kalos	Option	Director	52,378	0.4472%
06/04/23	Markus Warmuth	Option	Director	56,007	0.4782%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMV INC.	0.00%	0.00%	-	-	14
CHURCHILL CAPITAL CORP XI	-3.83%	-8.06%	-	-	69Cr
DRUGS MADE IN AMERICA ACQUISITION II CORP.	-0.07%	-0.07%	-	-	65Cr
BAIN CAPITAL GSS INVESTMENT CORP.	-0.10%	-0.24%	-	-	60Cr
CHURCHILL CAPITAL CORP XII	+0.46%	+0.65%	-	-	60Cr
CANTOR EQUITY PARTNERS IV, INC.	0.00%	-0.43%	+1.87%	-	59Cr
CENTIEL AG	+1.75%	+3.93%	+257.49%	-78.60%	58Cr
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.70%	-0.96%	-	-	56Cr
CHURCHILL CAPITAL CORP XIII	+0.76%	+0.66%	-	-	51Cr
Average	-0.19%	-0.50%	+129.68%	-78.60%	53.1Cr
Weighted average by Cap.	-0.30%	-0.73%	+128.63%	-78.60%